Suven Life Sciences Showcases CNS Pipeline at BIO 2026, Schedules 62 Global Partnering Meetings
New Delhi: Suven Life Sciences Limited has announced its participation in the BIO International Convention 2026, one of the world's largest biotechnology partnering conferences, scheduled to be held from June 22-25, 2026, in San Diego, USA. The clinical-stage biopharmaceutical company said it will use the global platform to showcase its differentiated portfolio of clinical candidates for central nervous system (CNS) disorders and explore strategic partnering opportunities with global pharmaceutical and biotechnology companies.
According to the company, delegates, investors and potential collaborators from large pharmaceutical and biotechnology companies will be welcomed at Booth #6154, where Suven will present its late-stage CNS pipeline addressing significant unmet medical needs. The portfolio includes clinical candidates targeting agitation in dementia of Alzheimer's type, major depressive disorder (MDD), narcolepsy, cognitive impairment associated with Parkinson's disease, and other CNS disorders.
Suven stated that it has scheduled 62 partnering meetings during the four-day event with the objective of exploring partnering strategies, out-licensing opportunities and co-development initiatives for its clinical-stage CNS assets.
The company delegation participating at BIO-2026 includes Venkat Jasti, Chairman and Managing Director; Ramakrishna Nirogi, President and Chief Scientific Officer; Anil Shinde, Vice President, Drug Chemistry; Pradeep Jayarajan, Vice President, Drug Biology; Vijay Benade, Associate Vice President, Drug Metabolism and Pharmacokinetics; and Satish Jetta, Associate Vice President, Quality Assurance and Regulatory.
Commenting on the participation, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said BIO-2026 provides an opportunity to showcase the company's progress across its clinical pipeline and engage with potential partners committed to addressing unmet needs in CNS disorders. He highlighted the positive Phase 2b results of Ropanicant in major depressive disorder, favourable Phase 1 results of SUVN-I6107, and the ongoing Phase 3 programmes of Masupirdine for agitation in dementia of Alzheimer's type and Samelisant under the AWAKE study for narcolepsy, adding that the company is looking to accelerate the development and commercialization of these assets through strategic collaborations.
The company also highlighted its differentiated CNS pipeline. Ropanicant (SUVN-911), an α4β2 receptor antagonist, is being developed as a novel antidepressant offering rapid onset of efficacy, pro-cognitive benefits and a favourable sexual side-effect profile. Following positive topline results from its Phase 2b proof-of-concept trial in major depressive disorder announced on June 17, 2026, Suven plans to initiate a global Phase 3 study during the first half of 2027.
Masupirdine (SUVN-502) is a 5-HT6 receptor antagonist being developed as a non-dopaminergic, non-sedative therapy for agitation in dementia of Alzheimer's type, with the potential to improve both behavioural symptoms and cognition. The company's global Phase 3 AWAKE study is currently 95% enrolled, with topline results expected in Q2 2027.
The company's Samelisant (SUVN-G3031) is designed as a non-controlled, non-stimulant H3 inverse agonist intended to improve wakefulness while offering a differentiated cardiovascular and drug-drug interaction profile compared with currently available therapies. A global Phase 3 study has been initiated for excessive daytime sleepiness (EDS) in narcolepsy, with topline results anticipated in Q2 2028.
Suven is also advancing Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist being developed for cognitive disorders. The company reported favourable safety, tolerability and dose-dependent pharmacokinetic findings in its Phase 1 study, while Phase 2 development is planned.
Another investigational candidate, SUVN-I6107, a muscarinic M1 true positive allosteric modulator (PAM), demonstrated favourable pharmacokinetics, safety and tolerability without cholinergic adverse events in a recently completed Phase 1 study. Pharmacodynamic assessments indicated improved alertness and information processing, and the company is planning a Phase 2 study.
Suven further stated that it owns the intellectual property rights for all of its clinical assets across major global markets, supporting its strategy of developing and commercialising innovative CNS therapies through strategic partnerships.
According to the Suven Life Sciences press release, participation at BIO International Convention 2026 forms part of the company's strategy to strengthen global collaborations, expand partnering opportunities and advance its portfolio of differentiated CNS therapies addressing major unmet medical needs.
